Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24

BMC Gastroenterology

Yi Cheng Chen¹  Ting Tsung Chang²  Chuan Mo Lee³  You Chen Chao⁴  Chao Wei Hsu¹ 

[1] Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 199 Tung Hwa North Road, Taipei, 105, Taiwan;National Cheng Kung University Hospital, Tainan, Taiwan;Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan;Buddhist Tzu Chi General Hospital, Taipei Branch, Taiwan

关键词: Roadmap concept;    HBV DNA kinetics;    Chronic hepatitis B;   

Others  :  858265
DOI  :  10.1186/1471-230X-12-178

 received in 2012-05-02, accepted in 2012-12-10,  发布年份 2012

【 摘 要 】

Background

The aims of this study were to compare results from a Taiwanese sub-study of the GLOBE 2303 telbivudine study and evaluate the HBV DNA kinetics.

Methods

Forty-one Taiwanese patients were treated for an additional 2 years with telbivudine. Efficacy endpoints were the same as the GLOBE study. The correlations of reductions in HBV DNA levels at Week 24 were evaluated.

Results

All 7 HBeAg-positive patients with undetectable HBV DNA levels at Week 24 sustained this response at Year 4 with rates of ALT normalization 71%, HBeAg seroconversion 57%, and cumulative resistance 0%. Out of 16 HBeAg-negative patients with undetectable HBV DNA levels at Week 24, 11 (78%) sustained this response at Year 4 with rates of ALT normalization 83% and cumulative resistance 8.7%. There were significant correlations between reductions of DNA of ≥5 log₁₀ copies/mL at Week 24 with maintained PCR negativity at Years 2–4 and a lack of resistance at Year 2.

Conclusions

Long-term telbivudine efficacy in Taiwanese patients was comparable to the GLOBE 2303 study. A reduction in HBV DNA levels by ≥5 log₁₀ copies/mL at Week 24 represented the optimal cut-off point, which may predict favourable outcomes in patients with high baseline HBV DNA levels.

Trial registration

ClinicalTrials.gov Identifier: NCT00142298 (http://clinicaltrials.gov/ webcite).

【 授权许可】

   
2012 Hsu et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, Hasnian SS, Leung N, Lesmana L, Phiet PH, Sjalfoellah Noer HM, Sollano J, Sun HS, Xu DZ: Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000, 15:1356-1361.
• [2]Kao JH: Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 2003, 46:400-407.
• [3]Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, Wan M, Chen C, Wu S, Chen Y, Xu J, Wang Q, Wei L, Chao G, Constance BF, Harb G, Brown NA, Jia J: Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology 2008, 47:447-454.
• [4]Chien RN: On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective. J Gastroenterol Hepatol 2010, 25:852-857.
• [5]Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA: Globe Study Group: Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576-2588.
• [6]Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV: GLOBE Study Group: 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486-495.
• [7]Gane EJ, Wang Y, Liaw YF, Hou J, Thongsawat S, Wan M, Moon YM, Jia J, Chao YC, Niu J, Leung N, Samuel D, Hsu CW, Bao W, Lopez P, Avila C: Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int 2011, 31:676-684.
• [8]Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, Buti M, Chutaputti A, Rasenack J, Hou J, O'Brien C, Nguyen TT, Jia J, Poynard T, Belanger B, Bao W, Naoumov NV: Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009, 51:11-20.
• [9]Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, Jacobson IM, Lim SG, Naoumov N, Marcellin P, Piratvisuth T, Zoulim F: Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007, 5:890-897.
• [10]Gane EJ: The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int 2008, 2:304-307.
• [11]Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J: Early hepatitis b virus dna reduction in hepatitis Be antigen-positive patients with chronic hepatitis b: a randomized international study of entecavir versus adefovir. Hepatol 2009, 49:72-79.
• [12]Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, Pawlotsky JM, Zoulim F: Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004, 9:679-693.
• [13]The 21st conference of the Asian pacific association for the study of the liver: oral presentations 17 February, 2011 Hepatol Int 2011, 5:3-558.
• [14]Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, Manns MP, Wedemeyer H, Naoumov NV: Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010, 52:1611-1620.
• [15]Hsu CW, Yeh CT, Chang ML, Liaw YF: Identification of a hepatitis B virus S gene mutant in lamividine-treated patients experiencing seroclearance. Gastroenterology 2007, 132:543-550.
• [16]Hsu CW, Yeh CT: Emergence of hepatitis B virus S gene mutants in patients experiencing HBsAg seroconversion after peginterferom therapy. Hepatology 2011, 54:101-108.
• [17]Moon YM, Hwang SG, Kim BS, Rim KS, Cho M, Kim DJ, Han JY, Kim YS, Choi HS, Ahn SH: [The efficacy and safety of telbivudine in Korean patients with chronic hepatitis B.]. Korean J Hepatol 2007, 13:503-512. In Korean
• [18]Seto WK, Lai CL, Fung J, Wong DK, Yuen JC, Hung IF, Yuen MF: Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol 2011, 55:522-528.
• [19]Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008, 6:1315-1341.
• [20]European Association for the study of the liver: EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
• [21]Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45:507-739.
• [22]Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001, 34:785-791.
• [23]Chan HL, Wong VW, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ: Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther 2007, 25:891-898.
• [24]Hass HG, Bock T, Nehls O, Kaiser S: Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. J Gastroenterol 2009, 44:871-877.
• [25]Osborn MK: Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther Clin Risk Manag 2009, 5:789-798.
• [26]Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S: Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2:263-283.